| 000 | 01525 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517151137.0 | ||
| 264 | 0 | _c20170509 | |
| 008 | 201705s 0 0 eng d | ||
| 022 | _a1536-5964 | ||
| 024 | 7 |
_a10.1097/MD.0000000000006606 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHe, Chao | |
| 245 | 0 | 0 |
_aThymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection. _h[electronic resource] |
| 260 |
_bMedicine _cApr 2017 |
||
| 300 |
_ae6606 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xdrug therapy |
| 650 | 0 | 4 |
_aChemotherapy, Adjuvant _xmethods |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSex Factors |
| 650 | 0 | 4 | _aThymalfasin |
| 650 | 0 | 4 |
_aThymosin _xadministration & dosage |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aPeng, Wei | |
| 700 | 1 | _aLi, Chuan | |
| 700 | 1 | _aWen, Tian-Fu | |
| 773 | 0 |
_tMedicine _gvol. 96 _gno. 16 _gp. e6606 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MD.0000000000006606 _zAvailable from publisher's website |
| 999 |
_c27093897 _d27093897 |
||